Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy
Identifieur interne : 001674 ( Main/Exploration ); précédent : 001673; suivant : 001675Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy
Auteurs : Martin Köllensperger [Autriche] ; Florian Krismer [Autriche] ; Anton Pallua [Autriche] ; Nadia Stefanova [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-02-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Animal model, Animals, Cell Death (drug effects), Convulsants (toxicity), Corpus Striatum (pathology), Disease Models, Animal, Dopamine and cAMP-Regulated Phosphoprotein 32 (metabolism), Drug Administration Schedule, EPO, Erythropoietin, Erythropoietin (therapeutic use), Exploratory Behavior (drug effects), Humans, MSA, Mice, Mice, Transgenic, Motor Activity (drug effects), Multiple System Atrophy (drug therapy), Multiple System Atrophy (genetics), Multiple System Atrophy (physiopathology), Multiple system atrophy, Myelin Proteolipid Protein (genetics), Nervous system diseases, Nitro Compounds (toxicity), Propionates (toxicity), Substantia Nigra (pathology), Tyrosine 3-Monooxygenase (metabolism), alpha-Synuclein (genetics), neuroprotection.
- MESH :
- chemical , genetics : Myelin Proteolipid Protein, alpha-Synuclein.
- chemical , metabolism : Dopamine and cAMP-Regulated Phosphoprotein 32, Tyrosine 3-Monooxygenase.
- chemical , therapeutic use : Erythropoietin.
- chemical , toxicity : Convulsants, Nitro Compounds, Propionates.
- drug effects : Cell Death, Exploratory Behavior, Motor Activity.
- drug therapy : Multiple System Atrophy.
- genetics : Multiple System Atrophy.
- pathology : Corpus Striatum, Substantia Nigra.
- physiopathology : Multiple System Atrophy.
- Animals, Disease Models, Animal, Drug Administration Schedule, Humans, Mice, Mice, Transgenic.
Abstract
Multiple system atrophy is a rapidly progressive neurodegenerative disorder with a markedly reduced life expectancy. Failure of symptomatic treatment raises an urgent need for disease‐modifying strategies. We have investigated the neuroprotective potential of erythropoietin in (proteolipid protein)‐α‐synuclein transgenic mice exposed to 3‐nitropropionic acid featuring multiple system atrophy‐like pathology including oligodendroglial α‐synuclein inclusions and selective neuronal degeneration. Mice were treated with erythropoietin starting before (early erythropoietin) and after (late erythropoietin) intoxication with 3‐nitropropionic acid. Nonintoxicated animals receiving erythropoietin and intoxicated animals treated with saline served as control groups. Behavioral tests included pole test, open field activity, and motor behavior scale. Immunohistochemistry for tyrosine hydroxylase and dopamine and cyclic adenosine monophosphate‐regulated phosphoprotein (DARPP‐32) was analyzed stereologically. Animals receiving erythropoietin before and after 3‐nitropropionic acid intoxication scored significantly lower on the motor behavior scale and they performed better in the pole test than controls with no significant difference between early and late erythropoietin administration. Similarly, rearing scores were worse in 3‐nitropropionic acid‐treated animals with no difference between the erythropoietin subgroups. Immunohistochemistry revealed significant attenuation of 3‐nitropropionic acid‐induced loss of tyrosine hydroxylase and DARPP‐32 positive neurons in substantia nigra pars compacta and striatum, respectively, in both erythropoietin‐treated groups without significant group difference in the substantia nigra. However, at striatal level, a significant difference between early and late erythropoietin administration was observed. In the combined (proteolipid protein)‐α‐synuclein 3‐nitropropionic acid multiple system atrophy mouse model, erythropoietin appears to rescue dopaminergic and striatal gabaergic projection neurons. This effect is associated with improved motor function. Further studies are warranted to develop erythropoietin as a potential interventional therapy in multiple system atrophy. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23474
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000298
- to stream Istex, to step Curation: 000298
- to stream Istex, to step Checkpoint: 000407
- to stream PubMed, to step Corpus: 001334
- to stream PubMed, to step Curation: 001334
- to stream PubMed, to step Checkpoint: 001354
- to stream Ncbi, to step Merge: 003092
- to stream Ncbi, to step Curation: 003092
- to stream Ncbi, to step Checkpoint: 003092
- to stream Main, to step Merge: 001728
- to stream PascalFrancis, to step Corpus: 000679
- to stream PascalFrancis, to step Curation: 002639
- to stream PascalFrancis, to step Checkpoint: 000614
- to stream Main, to step Merge: 001C04
- to stream Main, to step Curation: 001674
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy</title>
<author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name>
</author>
<author><name sortKey="Krismer, Florian" sort="Krismer, Florian" uniqKey="Krismer F" first="Florian" last="Krismer">Florian Krismer</name>
</author>
<author><name sortKey="Pallua, Anton" sort="Pallua, Anton" uniqKey="Pallua A" first="Anton" last="Pallua">Anton Pallua</name>
</author>
<author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A147CBC69A74C1D14A72A954D46F0F5D1E64744E</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23474</idno>
<idno type="url">https://api.istex.fr/document/A147CBC69A74C1D14A72A954D46F0F5D1E64744E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000298</idno>
<idno type="wicri:Area/Istex/Curation">000298</idno>
<idno type="wicri:Area/Istex/Checkpoint">000407</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Kollensperger M:erythropoietin:is:neuroprotective</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21462262</idno>
<idno type="wicri:Area/PubMed/Corpus">001334</idno>
<idno type="wicri:Area/PubMed/Curation">001334</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001354</idno>
<idno type="wicri:Area/Ncbi/Merge">003092</idno>
<idno type="wicri:Area/Ncbi/Curation">003092</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003092</idno>
<idno type="wicri:Area/Main/Merge">001728</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0211288</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000679</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002639</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000614</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Kollensperger M:erythropoietin:is:neuroprotective</idno>
<idno type="wicri:Area/Main/Merge">001C04</idno>
<idno type="wicri:Area/Main/Curation">001674</idno>
<idno type="wicri:Area/Main/Exploration">001674</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy</title>
<author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Krismer, Florian" sort="Krismer, Florian" uniqKey="Krismer F" first="Florian" last="Krismer">Florian Krismer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pallua, Anton" sort="Pallua, Anton" uniqKey="Pallua A" first="Anton" last="Pallua">Anton Pallua</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Division of Clinical Neurobiology, Department of Neurology, Medical University, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-02-15">2011-02-15</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="507">507</biblScope>
<biblScope unit="page" to="515">515</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">A147CBC69A74C1D14A72A954D46F0F5D1E64744E</idno>
<idno type="DOI">10.1002/mds.23474</idno>
<idno type="ArticleID">MDS23474</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term>
<term>Animals</term>
<term>Cell Death (drug effects)</term>
<term>Convulsants (toxicity)</term>
<term>Corpus Striatum (pathology)</term>
<term>Disease Models, Animal</term>
<term>Dopamine and cAMP-Regulated Phosphoprotein 32 (metabolism)</term>
<term>Drug Administration Schedule</term>
<term>EPO</term>
<term>Erythropoietin</term>
<term>Erythropoietin (therapeutic use)</term>
<term>Exploratory Behavior (drug effects)</term>
<term>Humans</term>
<term>MSA</term>
<term>Mice</term>
<term>Mice, Transgenic</term>
<term>Motor Activity (drug effects)</term>
<term>Multiple System Atrophy (drug therapy)</term>
<term>Multiple System Atrophy (genetics)</term>
<term>Multiple System Atrophy (physiopathology)</term>
<term>Multiple system atrophy</term>
<term>Myelin Proteolipid Protein (genetics)</term>
<term>Nervous system diseases</term>
<term>Nitro Compounds (toxicity)</term>
<term>Propionates (toxicity)</term>
<term>Substantia Nigra (pathology)</term>
<term>Tyrosine 3-Monooxygenase (metabolism)</term>
<term>alpha-Synuclein (genetics)</term>
<term>neuroprotection</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Myelin Proteolipid Protein</term>
<term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine and cAMP-Regulated Phosphoprotein 32</term>
<term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Erythropoietin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Convulsants</term>
<term>Nitro Compounds</term>
<term>Propionates</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Death</term>
<term>Exploratory Behavior</term>
<term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple System Atrophy</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Multiple System Atrophy</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Multiple System Atrophy</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Drug Administration Schedule</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Transgenic</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Atrophie multisystématisée</term>
<term>Erythropoïétine</term>
<term>Modèle animal</term>
<term>Pathologie du système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Multiple system atrophy is a rapidly progressive neurodegenerative disorder with a markedly reduced life expectancy. Failure of symptomatic treatment raises an urgent need for disease‐modifying strategies. We have investigated the neuroprotective potential of erythropoietin in (proteolipid protein)‐α‐synuclein transgenic mice exposed to 3‐nitropropionic acid featuring multiple system atrophy‐like pathology including oligodendroglial α‐synuclein inclusions and selective neuronal degeneration. Mice were treated with erythropoietin starting before (early erythropoietin) and after (late erythropoietin) intoxication with 3‐nitropropionic acid. Nonintoxicated animals receiving erythropoietin and intoxicated animals treated with saline served as control groups. Behavioral tests included pole test, open field activity, and motor behavior scale. Immunohistochemistry for tyrosine hydroxylase and dopamine and cyclic adenosine monophosphate‐regulated phosphoprotein (DARPP‐32) was analyzed stereologically. Animals receiving erythropoietin before and after 3‐nitropropionic acid intoxication scored significantly lower on the motor behavior scale and they performed better in the pole test than controls with no significant difference between early and late erythropoietin administration. Similarly, rearing scores were worse in 3‐nitropropionic acid‐treated animals with no difference between the erythropoietin subgroups. Immunohistochemistry revealed significant attenuation of 3‐nitropropionic acid‐induced loss of tyrosine hydroxylase and DARPP‐32 positive neurons in substantia nigra pars compacta and striatum, respectively, in both erythropoietin‐treated groups without significant group difference in the substantia nigra. However, at striatal level, a significant difference between early and late erythropoietin administration was observed. In the combined (proteolipid protein)‐α‐synuclein 3‐nitropropionic acid multiple system atrophy mouse model, erythropoietin appears to rescue dopaminergic and striatal gabaergic projection neurons. This effect is associated with improved motor function. Further studies are warranted to develop erythropoietin as a potential interventional therapy in multiple system atrophy. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><noRegion><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name>
</noRegion>
<name sortKey="Krismer, Florian" sort="Krismer, Florian" uniqKey="Krismer F" first="Florian" last="Krismer">Florian Krismer</name>
<name sortKey="Pallua, Anton" sort="Pallua, Anton" uniqKey="Pallua A" first="Anton" last="Pallua">Anton Pallua</name>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name>
<name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001674 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001674 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:A147CBC69A74C1D14A72A954D46F0F5D1E64744E |texte= Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy }}
This area was generated with Dilib version V0.6.23. |